Analyst Ratings For Diplomat Pharmacy (NYSE:DPLO)
Today, Diplomat Pharmacy (NYSE:DPLO) stock received an upgrade by Deutsche Bank from Hold to Buy.
Some recent analyst ratings include
- 3/2/2018-Deutsche Bank Upgrade from a “Hold ” rating to a ” Buy” rating.
- 2/27/2018-Wells Fargo & Co Reiterated Rating of Market Perform.
- 2/9/2018-Lake Street Capital initiated coverage with a Buy rating.
- 1/25/2018-Credit Suisse Group Upgrade from a “Underperform ” rating to a ” Neutral” rating.
Recent Insider Trading Activity For Diplomat Pharmacy (NYSE:DPLO)
Diplomat Pharmacy (NYSE:DPLO) has insider ownership of 30.20% and institutional ownership of 73.44%.
- On 11/20/2017 Atul Kavthekar, CFO, bought 2,000 with an average share price of $15.00 per share and the total transaction amounting to $30,000.00.
- On 11/20/2017 Jeffrey G Park, Director, bought 3,000 with an average share price of $15.46 per share and the total transaction amounting to $46,380.00.
- On 11/20/2017 Joel Saban, President, bought 10,000 with an average share price of $15.24 per share and the total transaction amounting to $152,400.00.
- On 9/15/2016 Atheer A Kaddis, EVP, sold 20,000 with an average share price of $30.12 per share and the total transaction amounting to $602,400.00.
- On 8/1/2016 Atheer A Kaddis, EVP, sold 12,325 with an average share price of $35.76 per share and the total transaction amounting to $440,742.00.
- On 7/1/2016 Atheer A Kaddis, EVP, sold 12,325 with an average share price of $35.04 per share and the total transaction amounting to $431,868.00.
- On 6/1/2016 Atheer A Kaddis, EVP, sold 12,325 with an average share price of $32.31 per share and the total transaction amounting to $398,220.75.
Recent Trading Activity for Diplomat Pharmacy (NYSE:DPLO)
Shares of Diplomat Pharmacy closed the previous trading session at 20.41 up +0.52 2.61% with 20.139999389648438 shares trading hands.